Head-to-head evidence
ACC017 vs Dolutegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
ACC017
Developed by Jiangsu Aidea Pharmaceutical Group
NCT06719310 · Phase 1/2 · completed
The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.
Next expected readout: June 2027 · NCT07711210 (registry estimate)
Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)
Marketed by ViiV Healthcare
NCT01263015 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACC017's landscape · Dolutegravir's landscape